verve therapeutics eli lilly

News

Lilly to buy gene-editing partner Verve

Eli Lilly’s $1.3 Billion Bid Sends Verve Therapeutics Stock Soaring. What to Know.

Lilly confirmed it would buy a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease.

· 2h

Eli Lilly to buy gene-editing biotech Verve for $1.3 billion

· 4h

Eli Lilly strikes deal to buy Crispr gene-editing biotech Verve

2hon MSN

This one-and-done heart-disease treatment just got a $1.3 billion endorsement from Eli Lilly

Verve Therapeutics’ stock was rallying by a record 80% on Eli Lilly’s premium purchase price for the drug-development company ...

1hon MSN

Why Verve Therapeutics Stock Is Skyrocketing Today

Shares of Verve Therapeutics ( VERV 76.56%) were skyrocketing 75.7% higher as of 10:50 a.m. ET on Tuesday. And for good reason. Eli Lilly ( LLY -0.90%) and Verve Therapeutics announced a "definitive ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

News

Lilly to buy gene-editing partner Verve

Trending now